This Cannabis Stock Is Down 95% From its All-Time High: Why the Rout May Not Be Over

The recent massive selloff in cannabis companies like The Green Organic Dutchman (TSX:TGOD) have seen may not be over — here’s why.

edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

With speculation around U.S. legalization growing, cannabis stocks have seen significant volatility of late. Indeed, this volatility is for good reason. A number of U.S. states have already legalized recreational cannabis. Accordingly, expectations of federal legalization seemed like a no-brainer with the “blue wave” we saw take hold in U.S. politics last year.

That said, it appears sentiment is starting to shift. Indeed, cannabis stocks have been roiled of late, as investors reprice this catalyst. Let’s discuss what this means for cannabis players like The Green Organic Dutchman (TSX:TGOD) right now.

An infrastructural loss

Like several other Canadian cannabis companies, TGOD was preparing for a growth spurt with U.S. legalization. Indeed, this company was positioning itself as a player with the potential to have export capacity to serve the United States. Its domestic production investments were substantial and were cheered by the market during previous bull markets.

However, domestic demand hasn’t really materialized to the extend TGOD expected. And with the U.S. export market increasingly looking out of reach, TGOD is yet another cannabis company to announce some significant writedowns.

The Green Organic Dutchman recently announced the sale of one of its Quebec facilities to Cannara Biotech. As a result of the deal, TGOD will receive US$27 million in proceeds.

However, the company’s total investment in this facility was US$229 million. Accordingly, the company will take a loss of more than US$200 million on this project. Indeed, the 185,000 kg of capacity this facility was supposed to provide has gone up in smoke, along with the US$200 million the company poured into this endeavour.

Indeed, such a drastic move is a sign of the times for the Canadian cannabis space. Companies are scrambling to cut costs. If that means taking massive losses, so be it.

Accordingly, investors looking at cannabis players like TGOD now may be wondering what they’re valuing. If these companies’ existing assets get revalued, things could turn ugly for these stocks. Indeed, one can make the argument some serious mismanagement of capital has taken place in this sector. How much gets written down before it’s all said and done is the big question many investors have right now.

Bottom line

The cannabis sector is a great example of a segment of the stock market that has seen valuations swing wildly. While some may argue that the selloffs we’ve seen have been as much of an overreaction as the parabolic spikes upward, this appears to be a true statement.

That said, the capital-allocation missteps of companies like TGOD stand as a reminder of what downside could be on the horizon for this sector. Indeed, over-exuberance for any asset class can turn out to be detrimental for long-term investors. In my view, this level of overexuberance still exists to some degree in the cannabis space today. Accordingly, further downside could be on the horizon for these stocks in the near to medium term.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any stocks mentioned in this article.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »